Apple polyphenols extract (APE) improves colon damage in a rat model of colitis

Digestive and Liver Disease

Volumn 44, Issue 7, 2012, Pages 555-562

  D'Argenio, Giuseppe ^a,b   Mazzone, Giovanna ^a   Tuccillo, Concetta ^c   Ribecco, Maria T ^a   Graziani, Giulia ^a   Gravina, Antonietta G ^c   Caserta, Sergio ^a,d   Guido, Stefano ^a,d   Fogliano, Vincenzo ^a   Caporaso, Nicola ^a   Romano, Marco ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Apple polyphenols; Calpain; Rat colitis; Tissue transglutaminase

Indexed keywords

ANTIINFLAMMATORY AGENT; APPLE EXTRACT; CALPAIN; CYCLOOXYGENASE 2; CYSTAMINE; GASTROINTESTINAL AGENT; MESSENGER RNA; PLANT EXTRACT; POLYPHENOL; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APPLE; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ISOLATION; ENZYME DEGRADATION; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION REGULATION; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; CALPAIN; COLITIS; CYCLOOXYGENASE 2; GTP-BINDING PROTEINS; INTESTINAL MUCOSA; MALE; MALUS; MICE; NIH 3T3 CELLS; PHYTOTHERAPY; PLANT EXTRACTS; POLYPHENOLS; RABBITS; RATS, WISTAR; RNA, MESSENGER; TRANSGLUTAMINASES; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861349298     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.01.009     Document Type: Article

References (38)

1. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
2. Nayar M., Rhodes J.M. Management of inflammatory bowel disease. Postgrad Med J 2004, 80:206-213.
3. Targan S. Current limitations of IBD treatment: where do we go from here?. Ann NY Acad Sci 2006, 1072:1-8.
4. Plevy S.E. Corticosteroid-sparing treatments in patients with Crohn's disease. Am J Gastroenterol 2002, 97:1607-1617.
5. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults (update). Am J Gastroenterol 2004, 99:1371-1385.
6. Travis S.P.L., Stange E.F., Le'mann M., et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008, 2:24-62.
7. Graziani G., D'Argenio G., Tuccillo C., et al. Apple polyphenol extracts prevent damage to human gastric epithelial cells in vitro and to rat gastric mucosa in vivo. Gut 2005, 54:193-200.
8. Ricciardiello L., Bazzoli F., Fogliano V. Phytochemicals and colorectal cancer prevention-myth or reality?. Nat Rev Gastroenterol Hepatol 2011, 8:592-596.
9. Le Marchand L., Murphy S.P., Hankin J.H., et al. Intake of flavonoids and lung cancer. J Natl Cancer Inst 2000, 92:154-160.
10. Tan A.C., Konczak I., Sze D.M., Ramzan I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr Cancer 2001, 63:495-505.
11. Greenberg C.S., Birckbichler P.J., Rice R.H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J 1991, 5:3071-3077. [review].
12. D'Argenio G., Calvani M., Della Valle N., et al. Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis. Gut 2005, 54:496-502.
13. Melloni E., Pontremoli S. The calpains. Trends Neurosci 1989, 12:438-444.
14. Zhang J., Guttmann R.P., Johnson G.V. Tissue transglutaminase is an in situ substrate of calpain: regulation of activity. J Neurochem 1998, 71:240-247.
15. Cuzzocrea S., McDonald M.C., Mazzon E., et al. Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. Gut 2001, 48:478-488.
16. Zhang J., Lesort M., Guttmann R.P., et al. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J Biol Chem 1998, 273:2288-2295.
17. D'Argenio G., Mazzone G., Tuccillo C., et al. Apple polyphenol extracts prevent aspirin-induced damage to the rat gastric mucosa. Br J Nutr 2008, 100:1228-1236.
18. Morris G.P., Beck P.L., Herridge M.S., et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
19. D'Argenio G., Cosenza V., Sorrentini I., et al. Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity. Gastroenterology 1994, 106:399-404.
20. Loguercio C., D'Argenio G., Delle Cave M., et al. Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats. Dig Dis Sci 1996, 41:1204-1211.
21. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-159.
22. Tuccillo C., Manzo B.A., D'Argenio G., et al. Up-regulation of heparin binding epidermal growth factor-like growth factor and amphiregulin expression in Helicobacter pylori-infected human gastric mucosa. Dig Liver Dis 2002, 34:498-505.
23. Zarrilli R., Tuccillo C., Santangelo M., et al. Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis. Am J Gastroenterol 1999, 94:3376-3378.
24. Upchurch H.F., Conway E., Patterson M.K., et al. Localization of cellular transglutaminase on the extracellular matrix after wounding: characteristics of the matrix bound enzyme. J Cell Physiol 1991, 149:375-382.
25. Hörmannsperger G., Haller D. Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. Int J Med Microbiol 2010, 300:63-73.
26. Sands B.E. Therapy of inflammatory bowel disease. Gastroenterology 2000, 118:S68-S82.
27. Langmead L., Dawson C., Hawkins C., et al. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther 2002, 16:197-205.
28. Qian Jia, Ivanov I., Zlatomir Z., et al. Dietary fish oil and curcumin combine to modulate colonic cytokinetics and gene expression in dextran sodium sulphate-treated mice. Br J Nutr 2011, 106:519-529.
29. Khan Z., Macdonald C., Wicks A.C., et al. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 2002, 16:1917-1922.
30. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007, 59:1073-1083.
31. Zhang J., Rodney P., Guttmann, et al. Tissue transglutaminase is an in situ substrate of calpain: regulation of activity. J Neurochem 1998, 71:240-247.
32. Sandborn W.J., Targan S.R. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002, 122:1592-1608.
33. Ferrante M., Vermeire S., Katsanos K.H., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13:123-128.
34. Myers K.J., Murthy S., Flanigan A., et al. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther 2003, 304:411-424.
35. Martín A.R., Villegas I., Alarcón de la Lastra C. The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res 2005, 54:145-151.
36. Kefalakes H., Stylianides T.J., Amanakis G., et al. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality?. Eur J Clin Pharmacol 2009, 65:963-970.
37. Cuzzocrea S., Mazzon E., Serraino I., et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor reduces the severity of experimental colitis induced by dinitrobenzene sulfonic acid in rats. Eur J Pharmacol 2001, 431:91-102.
38. Paiotti A.P.R., Miszputen S.J., Oshima C.T.F., et al. Effect of COX-2 inhibitor after TNBS-induced colitis in wistar rats. J Mol Hist 2009, 40:317-324.